Erectile Dysfunction - Market Insight, Epidemiology, and Market Forecast - 2034
Description
Key Highlights
The report analyzes the existing treatment practices and unmet medical requirements in Erectile Dysfunction. It evaluates the market potential and identifies potential business prospects for enhancing therapies or interventions. This valuable information enables stakeholders to make well-informed decisions regarding product development and strategic planning for the market.
Erectile Dysfunction Overview
Erectile dysfunction, previously known as impotence, refers to the consistent inability to achieve or maintain a firm penile erection sufficient for satisfactory sexual intercourse. Although some definitions suggest the condition must persist for at least six months, it commonly affects men over the age of 40 and becomes more prevalent with aging and comorbidities such as diabetes, hypertension, and cardiovascular disease. It may result from impaired blood flow, nerve damage, hormonal imbalances, or structural problems in penile tissue, with endothelial dysfunction often playing a central role.
While most cases of erectile dysfunction stem from physical causes, psychological factors may contribute, especially in younger individuals. Regardless of the underlying cause, the condition frequently leads to emotional distress, reduced self-esteem, strained relationships, and overall decreased quality of life for both the individual and their partner. As such, erectile dysfunction has significant medical and psychosocial implications.
Erectile Dysfunction Diagnosis and Treatment Algorithm
Identifying psychogenic causes of erectile dysfunction, especially in younger men, is crucial and can often be distinguished by sudden onset, situational dysfunction, normal morning or solo erections, or recent life changes. While most cases are organic, psychological support is often beneficial regardless of the cause, helping address anxiety, relationship stress, and treatment adherence. Mental health referrals should be normalized as part of routine care, much like any other diagnostic evaluation.
Initial evaluation does not require extensive testing; basic labs like complete blood count (CBC), metabolic panel, lipid profile, and morning testosterone may be done. Additional tests—such as penile biothesiometry, nocturnal tumescence testing, and penile Doppler ultrasound—are optional and used in selected cases to differentiate between vascular or neurological causes or to evaluate trauma-related dysfunction.
Erectile dysfunction is initially managed through lifestyle changes—such as exercise, a healthy diet, and addressing underlying conditions like diabetes or hypertension—along with psychological support when needed. First-line treatment typically involves oral phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil), which are effective in many men but require sexual stimulation.
For those who do not respond, options include alprostadil (administered intraurethrally or via injection), testosterone therapy in hypogonadal men, topical agents like Eroxon, and vacuum erection devices. Surgical implants offer a long-term solution for refractory cases. Experimental therapies like shockwave therapy, stem cells, and platelet-rich plasma remain under investigation.
Erectile Dysfunction Epidemiology
The epidemiology section of the Erectile Dysfunction market report offers information on the patient populations, including historical and projected trends for each of the seven major markets. Examining key opinion leader views from physicians or clinical experts can assist in identifying the reasons behind historical and projected trends. The diagnosed patient pool, their trends, and the underlying assumptions are all included in this section of the report.
This section also presents the data with relevant tables and graphs, offering a clear and concise view of the prevalence of Erectile Dysfunction. Additionally, the report discloses the assumptions made during the analysis, ensuring data interpretation and presentation transparency. This epidemiological data is valuable for understanding the disease burden and its impact on the patient population across various regions.
Key Findings
According to secondary sources, available data suggests that approximately 52% of men in the United States aged 40 to 70 experience erectile dysfunction. Overall, it is estimated that 30 to 50 million men in the US have erectile dysfunction.
According to secondary source, the prevalence of erectile dysfunction in men (age group 20 to 79 years) in Japan is approximately 30.9%, affecting around 14 million men.
As per secondary source, the prevalence of erectile dysfunction in Germany is approximately 21%, based on population data assessing male sexual dysfunctions.
Erectile Dysfunction Market Outlook
The Erectile Dysfunction therapeutics market is further expected to increase by the major drivers, such as the rising prevalence population, technological advancements, and upcoming therapies in the forecast period (2025–2034).
With ongoing research and continued dedication, the future holds hope for even more effective treatments and, ultimately, a cure for this challenging condition. According to DelveInsight, the Erectile Dysfunction market in the 7MM is expected to change significantly during the forecast period 2025–2034.
Erectile Dysfunction Drug Chapters
Emerging Erectile Dysfunction Drugs
The Erectile Dysfunction market is expected to evolve gradually, driven by the limited number of emerging therapies currently in development. Key players such as Bremelanotide + PDE5i, by Palatin Technologies, among others are showing active commitment to addressing this unmet need, with ongoing efforts to advance novel treatment options for this complex condition.
Bremelanotide + PDE5i: Palatin Technologies
Palatin has created a new single-injection co-formulation combining bremelanotide with a PDE5 inhibitor for the treatment of erectile dysfunction. The company plans to submit an Investigational New Drug (IND) application to the FDA later this year, with a potential Phase III trial targeting patients who do not respond to PDE5 inhibitor monotherapy.
In June 2024, Palatin Technologies announced the initiation of a Phase II clinical study of bremelanotide (BMT), a melanocortin 4 receptor (MC4R), co-administered with a phosphodiesterase 5 inhibitor (PDE5i), for the treatment of erectile dysfunction in patients that do not respond to PDE5i monotherapy.
Erectile Dysfunction Market Segmentation
DelveInsight’s ‘Erectile Dysfunction – Market Insights, Epidemiology, and Market Forecast – 2034’ report provides a detailed outlook of the current and future Erectile Dysfunction market, segmented within countries, by therapies, and by classes. Further, the market of each region is then segmented by each therapy to provide a detailed view of the current and future market share of all therapies.
Erectile Dysfunction Market Size by Countries
The Erectile Dysfunction market size is assessed separately for various countries, including the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan. In 2024, the United States held a significant share of the overall 7MM (Seven Major Markets) Erectile Dysfunction market, primarily attributed to the country’s higher prevalence of the condition and the elevated cost of the available treatments. This dominance is projected to persist, especially with the potential early introduction of new products.
Erectile Dysfunction Drugs Uptake
This section focuses on the sales uptake of potential Erectile Dysfunction drugs that have recently been launched or are anticipated to be launched in the Erectile Dysfunction market between 2020 and 2034. It estimates the market penetration of Erectile Dysfunction drugs for a given country, examining their impact within and across classes and segments. It also touches upon the financial and regulatory decisions contributing to the probability of success (PoS) of the drugs in the Erectile Dysfunction market.
The emerging Erectile Dysfunction therapies are analyzed based on various attributes such as safety and efficacy in randomized clinical trials, order of entry and other market dynamics, and the unmet need they fulfill in the Erectile Dysfunction market.
Note: Detailed assessment of drug uptake will be provided in the full report on Erectile Dysfunction.
Erectile Dysfunction Market Access and Reimbursement
DelveInsight’s ‘Erectile Dysfunction– Market Insights, Epidemiology, and Market Forecast – 2034’ report provides a descriptive overview of the market access and reimbursement scenario of Erectile Dysfunction.
This section includes a detailed analysis of the country-wise healthcare system for each therapy, enlightening the market access, reimbursement policies, and health technology assessments.
KOL Views
To keep up with current Erectile Dysfunction market trends and fill gaps in secondary findings, we interview KOLs and SMEs’ working in the Erectile Dysfunction domain. Their opinion helps understand and validate current and emerging therapies and treatment patterns or Erectile Dysfunction market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the Erectile Dysfunction unmet needs.
Erectile Dysfunction: KOL Insights
DelveInsight’s analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. These KOLs were from organizations, institutes, and hospitals, such as University of Minnesota Medical School, US, University of Ulm, Germany, University of Malaga, Spain, Nancy University, France, University of Birmingham, UK, and Osaka University Graduate School of Medicine Center, Japan, among others.
“Erectile function is controlled by a complex network involving primary afferents, spinal interneurons, and autonomic nerves. Neurological disorders can interfere with this regulation by impacting the endocrine or cardiovascular systems, and neuropathy, whether central or peripheral, is a known contributor to erectile dysfunction.”
“It’s important to distinguish between erectile dysfunction and premature ejaculation, as men may misreport symptoms. A man with premature ejaculation might claim erectile issues due to early loss of erection, while one with erectile dysfunction may report premature ejaculation from rushing to climax. Though often confused, both conditions can also occur simultaneously.”
“Diabetes is a major risk factor for erectile dysfunction, with evidence from both human and animal studies dating back to the 1970s. Chronic high blood sugar may impair nitric oxide production, disrupt the cGMP pathway, increase oxidative stress, activate the RhoA/Rho kinase pathway, and damage nerves. These mechanisms are believed to contribute to ED in diabetic patients.”
Note: Detailed assessment of KOL Views will be provided in the full report Erectile Dysfunction.
Competitive Intelligence Analysis
We conduct a Competitive and Market Intelligence analysis of the Erectile Dysfunction Market, utilizing various Competitive Intelligence tools such as SWOT analysis and Market entry strategies. The inclusion of these analyses is contingent upon data availability, ensuring a comprehensive and well-informed assessment of the market landscape and competitive dynamics.
Erectile Dysfunction Pipeline Development Activities
The report offers an analysis of therapeutic candidates in Phase II and III stages and examines companies involved in developing targeted therapeutics for Erectile Dysfunction. It provides valuable insights into the advancements and progress of potential treatments in clinical development for this condition.
Pipeline Development Activities
The report covers information on collaborations, acquisition and merger, licensing, patent details, and other information for emerging Erectile Dysfunction therapies.
Erectile Dysfunction Report Insights
1. What are the treatment goals for Erectile Dysfunction?
The main goals are to restore erectile function, improve sexual satisfaction and quality of life, and address underlying physical or psychological causes. Management also involves treating comorbidities, reducing distress, minimizing treatment side effects, and encouraging a healthy lifestyle to prevent progression.
2. What are the challenges in managing Erectile Dysfunction?
Managing erectile dysfunction is challenging due to its multifactorial causes, including vascular, neurological, hormonal, and psychological factors. Distinguishing between organic and psychogenic components requires careful evaluation. Long-term management is further complicated by comorbidities such as diabetes and cardiovascular disease, limited access to specialized care or advanced treatments, and issues with adherence, stigma, and treatment expectations. These factors can hinder effective, sustained improvement.
3. What are the key factors driving the growth of the Erectile Dysfunction market?
Key factors driving the growth of the erectile dysfunction market include increased awareness and reduced stigma surrounding men's sexual health, along with a rising prevalence of associated conditions such as diabetes, hypertension, and cardiovascular disease. Advances in oral pharmacotherapy, including next-generation PDE5 inhibitors and alternative delivery systems, have broadened treatment accessibility. Additionally, growing interest in regenerative therapies, improved healthcare access, and expanding telemedicine services are further accelerating market growth.
4. How will the Erectile Dysfunction Market and Epidemiology Forecast Report benefit the clients?
The report will provide comprehensive insights into the current Erectile Dysfunction market landscape, emerging therapies, competitive dynamics, regulatory requirements, and market access considerations, enabling informed decision-making, strategic planning, and optimization of business strategies to capitalize on market opportunities and drive growth.
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
- Erectile dysfunction is a common and complex condition that primarily affects men, with its occurrence increasing worldwide. It is defined by a persistent or recurring difficulty in achieving and sustaining an erection adequate for satisfying sexual activity.
- Erectile dysfunction has a multifactorial origin, involving organic, psychological, and combined causes, and is frequently associated with conditions like diabetes, cardiovascular issues, and neurological disorders. Its psychological and emotional effects can be significant, affecting both the individual and their partner.
- The erectile dysfunction market is projected to grow steadily from 2025 to 2034, driven by increasing global prevalence, heightened awareness, and wider acceptance of pharmacologic therapies. Continued innovation in oral PDE5 inhibitors, the emergence of regenerative approaches, and a robust clinical development pipeline are expected to support sustained market expansion and improved patient outcomes.
- Oral PDE5 inhibitors—sildenafil, tadalafil, vardenafil, and avanafil—along with alprostadil, form the core of FDA-approved pharmacologic therapies for erectile dysfunction. By enhancing penile blood flow, they provide effective, non-invasive treatment options with varying onset and duration profiles. Their introduction revolutionized ED management, improving quality of life and reducing reliance on surgical or device-based interventions.
- Palatin Technologies’ development of a combination therapy involving bremelanotide and PDE5 inhibitors signals a novel dual-mechanism approach to treating erectile dysfunction, particularly in patients unresponsive to monotherapy. By targeting both central arousal pathways through melanocortin receptor activation and enhancing peripheral vasodilation via PDE5 inhibition, this strategy exemplifies the growing trend toward personalized, multimodal interventions in sexual health aimed at improving efficacy and patient satisfaction.
- Erectile dysfunction market growth is fueled by advanced pharmacologic therapies and innovative formulations that enhance efficacy, speed of onset, and adherence. While oral PDE5 inhibitors remain the standard of care, their limitations such as inconsistent response and contraindications highlight the need for more personalized options. Emerging treatments, including novel delivery systems and regenerative approaches, aim to improve sexual function, satisfaction, and long-term outcomes.
The report analyzes the existing treatment practices and unmet medical requirements in Erectile Dysfunction. It evaluates the market potential and identifies potential business prospects for enhancing therapies or interventions. This valuable information enables stakeholders to make well-informed decisions regarding product development and strategic planning for the market.
Erectile Dysfunction Overview
Erectile dysfunction, previously known as impotence, refers to the consistent inability to achieve or maintain a firm penile erection sufficient for satisfactory sexual intercourse. Although some definitions suggest the condition must persist for at least six months, it commonly affects men over the age of 40 and becomes more prevalent with aging and comorbidities such as diabetes, hypertension, and cardiovascular disease. It may result from impaired blood flow, nerve damage, hormonal imbalances, or structural problems in penile tissue, with endothelial dysfunction often playing a central role.
While most cases of erectile dysfunction stem from physical causes, psychological factors may contribute, especially in younger individuals. Regardless of the underlying cause, the condition frequently leads to emotional distress, reduced self-esteem, strained relationships, and overall decreased quality of life for both the individual and their partner. As such, erectile dysfunction has significant medical and psychosocial implications.
Erectile Dysfunction Diagnosis and Treatment Algorithm
Identifying psychogenic causes of erectile dysfunction, especially in younger men, is crucial and can often be distinguished by sudden onset, situational dysfunction, normal morning or solo erections, or recent life changes. While most cases are organic, psychological support is often beneficial regardless of the cause, helping address anxiety, relationship stress, and treatment adherence. Mental health referrals should be normalized as part of routine care, much like any other diagnostic evaluation.
Initial evaluation does not require extensive testing; basic labs like complete blood count (CBC), metabolic panel, lipid profile, and morning testosterone may be done. Additional tests—such as penile biothesiometry, nocturnal tumescence testing, and penile Doppler ultrasound—are optional and used in selected cases to differentiate between vascular or neurological causes or to evaluate trauma-related dysfunction.
Erectile dysfunction is initially managed through lifestyle changes—such as exercise, a healthy diet, and addressing underlying conditions like diabetes or hypertension—along with psychological support when needed. First-line treatment typically involves oral phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil), which are effective in many men but require sexual stimulation.
For those who do not respond, options include alprostadil (administered intraurethrally or via injection), testosterone therapy in hypogonadal men, topical agents like Eroxon, and vacuum erection devices. Surgical implants offer a long-term solution for refractory cases. Experimental therapies like shockwave therapy, stem cells, and platelet-rich plasma remain under investigation.
Erectile Dysfunction Epidemiology
The epidemiology section of the Erectile Dysfunction market report offers information on the patient populations, including historical and projected trends for each of the seven major markets. Examining key opinion leader views from physicians or clinical experts can assist in identifying the reasons behind historical and projected trends. The diagnosed patient pool, their trends, and the underlying assumptions are all included in this section of the report.
This section also presents the data with relevant tables and graphs, offering a clear and concise view of the prevalence of Erectile Dysfunction. Additionally, the report discloses the assumptions made during the analysis, ensuring data interpretation and presentation transparency. This epidemiological data is valuable for understanding the disease burden and its impact on the patient population across various regions.
Key Findings
According to secondary sources, available data suggests that approximately 52% of men in the United States aged 40 to 70 experience erectile dysfunction. Overall, it is estimated that 30 to 50 million men in the US have erectile dysfunction.
According to secondary source, the prevalence of erectile dysfunction in men (age group 20 to 79 years) in Japan is approximately 30.9%, affecting around 14 million men.
As per secondary source, the prevalence of erectile dysfunction in Germany is approximately 21%, based on population data assessing male sexual dysfunctions.
Erectile Dysfunction Market Outlook
The Erectile Dysfunction therapeutics market is further expected to increase by the major drivers, such as the rising prevalence population, technological advancements, and upcoming therapies in the forecast period (2025–2034).
With ongoing research and continued dedication, the future holds hope for even more effective treatments and, ultimately, a cure for this challenging condition. According to DelveInsight, the Erectile Dysfunction market in the 7MM is expected to change significantly during the forecast period 2025–2034.
Erectile Dysfunction Drug Chapters
Emerging Erectile Dysfunction Drugs
The Erectile Dysfunction market is expected to evolve gradually, driven by the limited number of emerging therapies currently in development. Key players such as Bremelanotide + PDE5i, by Palatin Technologies, among others are showing active commitment to addressing this unmet need, with ongoing efforts to advance novel treatment options for this complex condition.
Bremelanotide + PDE5i: Palatin Technologies
Palatin has created a new single-injection co-formulation combining bremelanotide with a PDE5 inhibitor for the treatment of erectile dysfunction. The company plans to submit an Investigational New Drug (IND) application to the FDA later this year, with a potential Phase III trial targeting patients who do not respond to PDE5 inhibitor monotherapy.
In June 2024, Palatin Technologies announced the initiation of a Phase II clinical study of bremelanotide (BMT), a melanocortin 4 receptor (MC4R), co-administered with a phosphodiesterase 5 inhibitor (PDE5i), for the treatment of erectile dysfunction in patients that do not respond to PDE5i monotherapy.
Erectile Dysfunction Market Segmentation
DelveInsight’s ‘Erectile Dysfunction – Market Insights, Epidemiology, and Market Forecast – 2034’ report provides a detailed outlook of the current and future Erectile Dysfunction market, segmented within countries, by therapies, and by classes. Further, the market of each region is then segmented by each therapy to provide a detailed view of the current and future market share of all therapies.
Erectile Dysfunction Market Size by Countries
The Erectile Dysfunction market size is assessed separately for various countries, including the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan. In 2024, the United States held a significant share of the overall 7MM (Seven Major Markets) Erectile Dysfunction market, primarily attributed to the country’s higher prevalence of the condition and the elevated cost of the available treatments. This dominance is projected to persist, especially with the potential early introduction of new products.
Erectile Dysfunction Drugs Uptake
This section focuses on the sales uptake of potential Erectile Dysfunction drugs that have recently been launched or are anticipated to be launched in the Erectile Dysfunction market between 2020 and 2034. It estimates the market penetration of Erectile Dysfunction drugs for a given country, examining their impact within and across classes and segments. It also touches upon the financial and regulatory decisions contributing to the probability of success (PoS) of the drugs in the Erectile Dysfunction market.
The emerging Erectile Dysfunction therapies are analyzed based on various attributes such as safety and efficacy in randomized clinical trials, order of entry and other market dynamics, and the unmet need they fulfill in the Erectile Dysfunction market.
Note: Detailed assessment of drug uptake will be provided in the full report on Erectile Dysfunction.
Erectile Dysfunction Market Access and Reimbursement
DelveInsight’s ‘Erectile Dysfunction– Market Insights, Epidemiology, and Market Forecast – 2034’ report provides a descriptive overview of the market access and reimbursement scenario of Erectile Dysfunction.
This section includes a detailed analysis of the country-wise healthcare system for each therapy, enlightening the market access, reimbursement policies, and health technology assessments.
KOL Views
To keep up with current Erectile Dysfunction market trends and fill gaps in secondary findings, we interview KOLs and SMEs’ working in the Erectile Dysfunction domain. Their opinion helps understand and validate current and emerging therapies and treatment patterns or Erectile Dysfunction market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the Erectile Dysfunction unmet needs.
Erectile Dysfunction: KOL Insights
DelveInsight’s analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. These KOLs were from organizations, institutes, and hospitals, such as University of Minnesota Medical School, US, University of Ulm, Germany, University of Malaga, Spain, Nancy University, France, University of Birmingham, UK, and Osaka University Graduate School of Medicine Center, Japan, among others.
“Erectile function is controlled by a complex network involving primary afferents, spinal interneurons, and autonomic nerves. Neurological disorders can interfere with this regulation by impacting the endocrine or cardiovascular systems, and neuropathy, whether central or peripheral, is a known contributor to erectile dysfunction.”
“It’s important to distinguish between erectile dysfunction and premature ejaculation, as men may misreport symptoms. A man with premature ejaculation might claim erectile issues due to early loss of erection, while one with erectile dysfunction may report premature ejaculation from rushing to climax. Though often confused, both conditions can also occur simultaneously.”
“Diabetes is a major risk factor for erectile dysfunction, with evidence from both human and animal studies dating back to the 1970s. Chronic high blood sugar may impair nitric oxide production, disrupt the cGMP pathway, increase oxidative stress, activate the RhoA/Rho kinase pathway, and damage nerves. These mechanisms are believed to contribute to ED in diabetic patients.”
Note: Detailed assessment of KOL Views will be provided in the full report Erectile Dysfunction.
Competitive Intelligence Analysis
We conduct a Competitive and Market Intelligence analysis of the Erectile Dysfunction Market, utilizing various Competitive Intelligence tools such as SWOT analysis and Market entry strategies. The inclusion of these analyses is contingent upon data availability, ensuring a comprehensive and well-informed assessment of the market landscape and competitive dynamics.
Erectile Dysfunction Pipeline Development Activities
The report offers an analysis of therapeutic candidates in Phase II and III stages and examines companies involved in developing targeted therapeutics for Erectile Dysfunction. It provides valuable insights into the advancements and progress of potential treatments in clinical development for this condition.
Pipeline Development Activities
The report covers information on collaborations, acquisition and merger, licensing, patent details, and other information for emerging Erectile Dysfunction therapies.
Erectile Dysfunction Report Insights
- Erectile Dysfunction Patient Population
- Therapeutic Approaches
- Erectile Dysfunction Pipeline Analysis
- Erectile Dysfunction Market Size and Trends
- Erectile Dysfunction Market Opportunities
- Impact of Upcoming Therapies
- 10 Years Forecast
- The 7MM Coverage
- Erectile Dysfunction Epidemiology Segmentation
- Key Cross Competition
- Highly Analyzed Erectile Dysfunction Market
- Erectile Dysfunction Drugs Uptake
- Erectile Dysfunction Current Treatment Practices
- Unmet Needs
- Erectile Dysfunction Pipeline Product Profiles
- Erectile Dysfunction Market Attractiveness
- How common is Erectile Dysfunction?
- What are the key findings of Erectile Dysfunction epidemiology across the 7MM, and which country will have the highest number of patients during the study period (2020–2034)?
- What are the currently available treatments for Erectile Dysfunction?
- What are the disease risk, burden, and unmet needs of Erectile Dysfunction?
- At what CAGR is the Erectile Dysfunction market and its epidemiology is expected to grow in the 7MM during the forecast period (2025–2034)?
- How would the unmet needs impact the Erectile Dysfunction market dynamics and subsequently influence the analysis of the related trends?
- What would be the forecasted patient pool of Erectile Dysfunction in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
- Among EU4 and the UK, which country will have the highest number of patients during the forecast period (2025–2034)?
- How many companies are currently developing therapies for the treatment of Erectile Dysfunction?
- The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the Erectile Dysfunction Market.
- Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
- To understand the existing market opportunity in varying geographies and the growth potential over the coming years.
- Distribution of historical and current patient share based on real-world prescription data along with reported sales of current treatment in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
- Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
- Highlights of Access and Reimbursement policies of approved therapies, barriers to accessibility of off-label expensive therapies, and patient assistance programs.
- To understand the perspective of Key Opinion Leaders around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
- Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
1. What are the treatment goals for Erectile Dysfunction?
The main goals are to restore erectile function, improve sexual satisfaction and quality of life, and address underlying physical or psychological causes. Management also involves treating comorbidities, reducing distress, minimizing treatment side effects, and encouraging a healthy lifestyle to prevent progression.
2. What are the challenges in managing Erectile Dysfunction?
Managing erectile dysfunction is challenging due to its multifactorial causes, including vascular, neurological, hormonal, and psychological factors. Distinguishing between organic and psychogenic components requires careful evaluation. Long-term management is further complicated by comorbidities such as diabetes and cardiovascular disease, limited access to specialized care or advanced treatments, and issues with adherence, stigma, and treatment expectations. These factors can hinder effective, sustained improvement.
3. What are the key factors driving the growth of the Erectile Dysfunction market?
Key factors driving the growth of the erectile dysfunction market include increased awareness and reduced stigma surrounding men's sexual health, along with a rising prevalence of associated conditions such as diabetes, hypertension, and cardiovascular disease. Advances in oral pharmacotherapy, including next-generation PDE5 inhibitors and alternative delivery systems, have broadened treatment accessibility. Additionally, growing interest in regenerative therapies, improved healthcare access, and expanding telemedicine services are further accelerating market growth.
4. How will the Erectile Dysfunction Market and Epidemiology Forecast Report benefit the clients?
The report will provide comprehensive insights into the current Erectile Dysfunction market landscape, emerging therapies, competitive dynamics, regulatory requirements, and market access considerations, enabling informed decision-making, strategic planning, and optimization of business strategies to capitalize on market opportunities and drive growth.
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
Table of Contents
200 Pages
- 1. Key Insights
- 2. Report Introduction
- 3. Market Overview at a Glance
- 3.1.. Market Share (%) Distribution by Therapies in 2024
- 3.2.. Market Share (%) Distribution by Therapies in 2034
- 4. Epidemiology and Market Methodology
- 5. Executive Summary
- 6. Key Events
- 7. Disease Background and Overview
- 7.1.. Introduction
- 7.2. Types
- 7.3.. Causes
- 7.4.. Pathophysiology
- 7.5.. Symptoms
- 7.6.. Risk Factor
- 7.7.. Diagnosis
- 7.7.1.. Diagnostic Algorithm
- 7.7.2.. Diagnostic Guidelines
- 7.8.. Treatment and Management
- 7.8.1.. Treatment Algorithm
- 7.8.2.. Treatment Guidelines
- 8. Epidemiology and Patient Population
- 8.1. Key Findings
- 8.2. Assumptions and Rationale: The 7MM
- 8.3. Total Prevalent Cases of Erectile Dysfunction in the 7MM
- 8.4. Total Diagnosed Prevalent Cases of Erectile Dysfunction in the 7MM
- 8.5. The US
- 8.5.1. Total Prevalent Cases of Erectile Dysfunction
- 8.5.2. Total Diagnosed Prevalent Cases of Erectile Dysfunction
- 8.5.3. Age-specific Cases of Erectile Dysfunction
- 8.5.4. Etiology-specific Cases of Erectile Dysfunction
- 8.5.5. Treated Cases of Erectile Dysfunction
- 8.6. EU4 and the UK
- 8.6.1. Total Prevalent Cases of Erectile Dysfunction
- 8.6.2. Total Diagnosed Prevalent Cases of Erectile Dysfunction
- 8.6.3. Age-specific Cases of Erectile Dysfunction
- 8.6.4. Etiology-specific Cases of Erectile Dysfunction
- 8.6.5. Treated Cases of Erectile Dysfunction
- 8.7. Japan
- 8.7.1. Total Prevalent Cases of Erectile Dysfunction
- 8.7.2. Total Diagnosed Prevalent Cases of Erectile Dysfunction
- 8.7.3. Age-specific Cases of Erectile Dysfunction
- 8.7.4. Etiology-specific Cases of Erectile Dysfunction
- 8.7.5. Treated Cases of Erectile Dysfunction
- 9. Patient Journey
- 10. Emerging Therapies
- 10.1. Key Cross Competition
- 10.2. Bremelanotide + PDE5i: Palatin Technologies
- 10.2.1. Drug Description
- 10.2.2. Other Development Activities
- 10.2.3. Clinical Trials Information
- 10.2.4. Safety and Efficacy
- 10.2.5. Analysts’ Views
- 11. Erectile Dysfunction: Seven Major Market Analysis
- 11.1. Key Findings
- 11.2. Key Market Forecast Assumptions
- 11.2.1. Cost Assumptions and Rebates
- 11.2.2. Pricing Trends
- 11.2.3. Analogue Assessment
- 11.2.4. Launch Year and Therapy Uptake
- 11.3. Market Outlook
- 11.4. Total Market Size of Erectile Dysfunction in the 7MM
- 11.5. Market Size of Erectile Dysfunction by Therapies in the 7MM
- 11.6. The US Market Size
- 11.6.1. Total Market Size of Erectile Dysfunction
- 11.6.2. Market Size of Erectile Dysfunction by Therapies
- 11.7. EU4 and the UK Market Size
- 11.7.1. Total Market Size of Erectile Dysfunction
- 11.7.2. Market Size of Erectile Dysfunction by Therapies
- 11.8.. Japan Market Size
- 11.8.1. Total Market Size of Erectile Dysfunction
- 11.8.2. Market Size of Erectile Dysfunction by Therapies
- 12. Key Opinion Leaders’ Views
- 13. Unmet Needs
- 14. SWOT Analysis
- 15. Erectile Dysfunction Market Access and Reimbursement
- 15.1. United States
- 15.1.1. Centre for Medicare and Medicaid Services (CMS)
- 15.2. EU4 and the UK
- 15.2.1. Germany
- 15.2.2. France
- 15.2.3. Italy
- 15.2.4. Spain
- 15.2.5. United Kingdom
- 15.3. Japan
- 15.3.1. MHLW
- 16. Appendix
- 16.1. Bibliography
- 16.2. Abbreviations and Acronyms
- 16.3. Report Methodology
- 17. DelveInsight Capabilities
- 18. Disclaimer
- 19. About DelveInsight
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
